P. Paquis and . Épidémiologie, Rev Neurol, vol.168, p.217, 2012.

;. Meningiomas and M. D. Cushing, Their classification, regional behaviour, life history, and surgical end results

I. Springfield and M. Baltimore, BJS, vol.26, issue.104, pp.957-957, 1939.

F. T. Charbel, H. Hyun, M. Misra, S. Gueyikian, R. F. Mafee et al., Report of Four Cases and Review of Literature, Radiol Clin North Am, vol.37, issue.1, pp.89-100, 1999.

O. De-jesús and M. M. Toledo, Surgical management of meningioma en plaque of the sphenoid ridge, Surg Neurol, vol.55, issue.5, pp.265-274, 2001.

A. Nanda, S. C. Bir, T. K. Maiti, S. K. Konar, S. Missios et al., Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma, J Neurosurg, 2017.

S. Cha, Update on Brain Tumor Imaging: From Anatomy to Physiology, Am J Neuroradiol, 2006.

C. G. Filippi, M. A. Edgar, A. M. Ulu?, J. C. Prowda, L. A. Heier et al., Appearance of Meningiomas on

, Diffusion-weighted Images: Correlating Diffusion Constants with Histopathologic Findings, Am J Neuroradiol, 2001.

H. Zhang, L. A. Rödiger, T. Shen, J. Miao, and M. Oudkerk, Preoperative subtyping of meningiomas by perfusion MR imaging, Neuroradiology, vol.50, issue.10, p.835, 2008.

U. Cremerius, E. Striepecke, W. Henn, J. Weis, M. Mull et al.,

, Nukl Nucl Med, 1994.

B. Lippitz, U. Cremerius, L. Mayfrank, H. Bertalanffy, R. Raoofi et al., PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate, Acta Neurochir Suppl, vol.65, pp.108-119, 1996.

N. Galldiks, N. L. Albert, M. Sommerauer, A. L. Grosu, U. Ganswindt et al., PET imaging in patients with meningioma-report of the RANO/PET Group, vol.19, pp.1576-87, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02940559

M. J. Riemenschneider, A. Perry, and G. Reifenberger, Histological classification and molecular genetics of meningiomas, Lancet Neurol, vol.5, issue.12, pp.1045-54, 2006.

D. N. Louis, A. Perry, G. Reifenberger, A. Von-deimling, D. Figarella-branger et al., , 2016.

, World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol (Berl), vol.131, issue.6, pp.803-823, 2016.

S. Goutagny, J. C. Nault, M. Mallet, D. Henin, J. Z. Rossi et al., High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression, Brain Pathol, vol.24, issue.2, pp.184-193, 2014.

R. Goldbrunner, G. Minniti, M. Preusser, M. D. Jenkinson, K. Sallabanda et al., EANO guidelines for the diagnosis and treatment of meningiomas, Lancet Oncol, vol.17, issue.9, pp.383-91, 2016.

S. Soyuer, E. L. Chang, U. Selek, W. Shi, M. H. Maor et al., Radiotherapy after surgery for benign cerebral meningioma, Radiother Oncol, vol.71, issue.1, pp.85-90, 2004.

J. Antinheimo, R. Sankila, O. Carpén, E. Pukkala, M. Sainio et al., Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas, Neurology, vol.54, issue.1, pp.71-77, 2000.

B. Asgharian, Y. Chen, N. J. Patronas, P. L. Peghini, J. C. Reynolds et al., Meningiomas may be a component tumor of multiple endocrine neoplasia type 1, Clin Cancer Res Off J Am Assoc Cancer Res, vol.10, issue.3, pp.869-80, 2004.

D. L. Preston, R. E. Yonehara, S. Kobuke, T. Fujii, H. Kishikawa et al., Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure, J Natl Cancer Inst, vol.94, issue.20, pp.1555-63, 2002.

J. Wiemels, M. Wrensch, and E. B. Claus, Epidemiology and etiology of meningioma, J Neurooncol, 2010.

S. Pravdenkova, O. Al-mefty, J. Sawyer, and M. Husain, Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas, J Neurosurg, vol.105, issue.2, pp.163-73, 2006.

J. W. Beks and H. L. De-windt, The recurrence of supratentorial meningiomas after surgery, Acta Neurochir (Wien), vol.95, issue.1-2, pp.3-5, 1988.

A. B. Adegbite, M. I. Khan, K. W. Paine, and L. K. Tan, The recurrence of intracranial meningiomas after surgical treatment, J Neurosurg, vol.58, issue.1, pp.51-57, 1983.

D. Simpson, . The, . Of, . Meningiomas, and . Surgical-treatment, J Neurol Neurosurg Psychiatry, vol.20, issue.1, pp.22-39, 1957.

S. L. Mcgovern, K. D. Aldape, M. F. Munsell, A. Mahajan, F. Demonte et al., A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas, J Neurosurg, vol.112, issue.5, pp.925-958, 2010.

J. Ayerbe, R. D. Lobato, J. De-la-cruz, R. Alday, J. J. Rivas et al., Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis, Acta Neurochir

R. E. Mantle, B. Lach, M. R. Delgado, S. Baeesa, and G. Bélanger, Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning, J Neurosurg, vol.91, issue.3, pp.375-83, 1999.

M. K. Aghi, B. S. Carter, G. R. Cosgrove, R. G. Ojemann, S. Amin-hanjani et al., Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation, Neurosurgery, vol.64, issue.1, pp.56-60, 2009.

H. Yoon, M. P. Mehta, K. Perumal, I. B. Helenowski, R. J. Chappell et al., Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy, J Cancer Res Ther, vol.11, issue.1, pp.59-66, 2015.

C. Boskos, L. Feuvret, G. Noel, J. Habrand, P. Pommier et al., Combined Proton and Photon

, Conformal Radiotherapy for Intracranial Atypical and Malignant Meningioma, Int J Radiat Oncol ? Biol ? Phys, 2009.

, Oct, vol.1, issue.2, pp.399-406

L. Moyal, C. Vignal-clermont, H. Boissonnet, and C. Alapetite, Résultats de la protonthérapie ciblée fractionnée

T. Kaley, I. Barani, M. Chamberlain, M. Mcdermott, K. Panageas et al., Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: a RANO review, Neuro-Oncol, 2014.

M. Wahab and F. Al-azzawi, Meningioma and hormonal influences, Climacteric J Int Menopause Soc, 2003.

Y. Ji, C. Rankin, S. Grunberg, A. E. Sherrod, J. Ahmadi et al., Double-Blind Phase III

, Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005, J Clin Oncol, vol.33, issue.34, pp.4093-4101, 2015.

R. Sharma, K. Garg, V. Katiyar, V. Tandon, D. Agarwal et al., The role of mifepristone in the management of meningiomas: A systematic review of literature, Acta Neurol Scand, vol.67, issue.3, pp.434-440, 1987.

R. Teijeiro, R. Rios, J. Costoya, R. Castro, J. Bello et al., Activation of Human Somatostatin Receptor 2 Promotes Apoptosis Through a Mechanism that is Independent from Induction of p53, Cell Physiol Biochem, vol.12, issue.1, pp.31-39, 2002.

C. Bousquet, J. Guillermet-guibert, N. Saint-laurent, E. Archer-lahlou, F. Lopez et al., Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway, EMBO J, 2006.

, Sep, vol.6, issue.17, pp.3943-54

J. C. Watson, D. A. Balster, B. M. Gebhardt, T. M. O'dorisio, O. 'dorisio et al., Growing vascular endothelial cells express somatostatin subtype 2 receptors, Br J Cancer, vol.85, issue.2, pp.266-72, 2001.

R. D. Murray, K. Kim, S. Ren, M. Chelly, Y. Umehara et al., Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis, J Clin Invest, vol.114, issue.3, pp.349-56, 2004.

T. Graillon, D. Romano, C. Defilles, A. Saveanu, A. Mohamed et al., Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review, J Neurosurg, vol.127, issue.3, pp.660-669, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01478922

T. Graillon, M. Sanson, C. Campello, A. Idbaih, M. Peyre et al., Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial, Clin Cancer Res, vol.26, issue.3, pp.552-559, 2020.
URL : https://hal.archives-ouvertes.fr/hal-02457059

P. Y. Wen, W. Yung, K. R. Lamborn, A. D. Norden, T. F. Cloughesy et al., Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08), Neuro-Oncol, 2009.

A. D. Norden, J. J. Raizer, L. E. Abrey, K. R. Lamborn, A. B. Lassman et al., Phase II Trials of Erlotinib or Gefitinib in Patients with Recurrent Meningioma, J Neurooncol, vol.96, issue.2, p.211, 2010.

K. Lamszus, U. Lengler, N. O. Schmidt, D. Stavrou, S. Ergün et al., Vascular Endothelial Growth Factor

, Basic Fibroblast Growth Factor, and Placenta Growth Factor in Human Meningiomas and Their Relation to Angiogenesis and Malignancy, Neurosurgery, vol.46, issue.4, pp.938-986, 2000.

R. O. Mirimanoff, D. E. Dosoretz, R. M. Linggood, R. G. Ojemann, and R. L. Martuza, Meningioma: analysis of recurrence and progression following neurosurgical resection, J Neurosurg, vol.62, issue.1, pp.18-24, 1985.

S. Hammouche, S. Clark, A. Wong, P. Eldridge, and J. O. Farah, Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment, Acta Neurochir, 2014.

M. E. Sughrue, N. Sanai, G. Shangari, A. T. Parsa, M. S. Berger et al., Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas: Clinical article, J Neurosurg

, Principe et technique de la tomographie par émission de positons (TEP), vol.1, pp.2-35, 2004.

G. B. Saha, W. J. Macintyre, and R. T. Go, Cyclotrons and positron emission tomography radiopharmaceuticals for clinical imaging, Semin Nucl Med, vol.22, issue.3, pp.150-61, 1992.

A. I. Kassis and S. J. Adelstein, Radiobiologic Principles in Radionuclide Therapy, J Nucl Med, vol.46, issue.1, pp.4-12, 2005.

J. Pouget and S. J. Mather, General aspects of the cellular response to low-and high-LET radiation, Eur J Nucl Med, vol.28, issue.4, pp.541-61, 2001.

J. Pouget, C. Lozza, E. Deshayes, V. Boudousq, and I. Navarro-teulon, Subjecting Radiologic Imaging to the Linear No-Threshold Hypothesis: A Non Sequitur of Non-Trivial Proportion, J Nucl Med, vol.2, issue.1, pp.1-6, 2015.

S. Burdak-rothkamm and K. Rothkamm, Radiation-induced bystander and systemic effects serve as a unifying model system for genotoxic stress responses, Mutat Res Mutat Res, vol.778, pp.13-22, 2018.

S. Siva, M. P. Macmanus, R. F. Martin, and O. A. Martin, Abscopal effects of radiation therapy: A clinical review for the radiobiologist, Cancer Lett, vol.356, issue.1, pp.82-90, 2015.

W. Ngwa, O. C. Irabor, J. D. Schoenfeld, J. Hesser, S. Demaria et al., Using immunotherapy to boost the abscopal effect, Nat Rev Cancer, vol.18, issue.5, pp.313-335, 2018.

M. Ljungberg, A. Celler, M. W. Konijnenberg, K. F. Eckerman, Y. K. Dewaraja et al.,

, Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy, J Nucl Med, vol.57, issue.26, pp.151-62, 2016.

E. Ilan, M. Sandström, C. Wassberg, A. Sundin, U. Garske-román et al., Dose Response

, Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, J Nucl Med, vol.56, issue.2, pp.177-82, 2015.

J. Reubi, B. Waser, J. Schaer, and J. A. Laissue, Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands, Eur J Nucl Med, vol.28, issue.7, pp.836-882, 2001.

F. Alderton, T. P. Fan, M. Schindler, and P. P. Humphrey, Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation, Br J Pharmacol, vol.125, issue.8, pp.1630-1633, 1998.

S. Arena, F. Barbieri, S. Thellung, P. Pirani, A. Corsaro et al., Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity, J Neurooncol, vol.66, issue.1-2, pp.155-66, 2004.

O. Silva-cb-de, B. R. Ongaratti, G. Trott, T. Haag, N. P. Ferreira et al., Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance, Int J Clin Exp Pathol, vol.8, issue.10, pp.13185-92, 2015.

J. C. Reubi, B. Waser, H. M. Markusse, E. P. Krenning, M. Vanhagen et al., Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis, Eur J Pharmacol, vol.271, issue.2-3, pp.371-379, 1994.

A. Tsutsumi, H. Takano, K. Ichikawa, S. Kobayashi, and T. Koike, Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells, Cell Immunol, vol.181, issue.1, pp.44-53, 1997.

F. Lagrange, . Radiopharmacie, G. Médicaments-radiopharmaceutiques, M. Galy, . Fraysse et al., , vol.438, p.9782743014438, 2012.

J. Fichna and A. Janecka, Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging

, Bioconjug Chem, vol.14, issue.1, pp.3-17, 2003.

I. Velikyan, Prospective of 68Ga-Radiopharmaceutical Development. Theranostics, vol.4, pp.47-80, 2013.

I. Virgolini, V. Ambrosini, J. B. Bomanji, R. P. Baum, S. Fanti et al., Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, p.68

, Eur J Nucl Med Mol Imaging, vol.37, issue.10, pp.2004-2014, 2010.

M. S. Hofman, W. Lau, and R. J. Hicks, Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation, 2015.

, Apr, vol.35, issue.2, pp.500-516

V. Froeling, R. Röttgen, F. Collettini, J. Rothe, B. Hamm et al., Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of, vol.58, issue.3, pp.310-318, 2014.

A. Kroiss, D. Putzer, C. Decristoforo, C. Uprimny, B. Warwitz et al., 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT, Eur J Nucl Med Mol Imaging, vol.40, issue.4, pp.514-537, 2013.

A. Afshar-oromieh, M. B. Wolf, C. Kratochwil, F. L. Giesel, S. E. Combs et al.,

, Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro-Oncol, vol.17, pp.312-321, 2015.

A. Klingenstein, A. R. Haug, C. Miller, and C. Hintschich, Ga-68-DOTA-TATE PET/CT for Discrimination of Tumors of the Optic Pathway, Orbit, vol.34, issue.1, pp.16-22, 2015.

M. Sommerauer, J. Burkhardt, K. Frontzek, E. Rushing, A. Buck et al., Gallium, vol.68

, DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? Neuro-Oncol, vol.18, pp.1021-1028, 2016.

E. Gay, J. P. Vuillez, O. Palombi, P. Y. Brard, P. Bessou et al., Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas, Neurosurgery, vol.57, issue.1, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00391007

W. Rachinger, V. M. Stoecklein, N. A. Terpolilli, A. R. Haug, L. Ertl et al., Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue, J Nucl Med, vol.56, issue.3, pp.347-53, 2015.

M. Henze, J. Schuhmacher, P. Hipp, J. Kowalski, D. W. Becker et al., PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas, J Nucl Med Off Publ Soc Nucl Med, vol.42, issue.7, pp.1053-1059, 2001.

R. Graf, F. Nyuyki, I. G. Steffen, R. Michel, D. Fahdt et al., Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy, Int J Radiat Oncol Biol Phys, vol.85, issue.1, pp.68-73, 2013.

S. Milker-zabel, Z. Bois, A. Henze, M. Huber, P. Schulz-ertner et al., Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET, Int J Radiat Oncol Biol Phys, vol.65, issue.1, pp.222-229, 2006.

B. Gehler, F. Paulsen, M. O. Oksüz, T. Hauser, S. M. Eschmann et al., DOTATOC-PET/CT for meningioma IMRT treatment planning, Radiat Oncol Lond Engl, vol.68, p.56, 2009.

F. Stade, J. Dittmar, O. Jäkel, C. Kratochwil, U. Haberkorn et al., Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy, Radiat Oncol Lond Engl, vol.13, issue.1, p.58, 2018.

K. A. Kessel, W. Weber, I. Yakushev, H. Fischer, T. Voglhuber et al., Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome, Eur J Nucl Med Mol Imaging, 2019.

A. Grosu, W. A. Weber, S. T. Astner, M. Adam, B. J. Krause et al., 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy, Int J Radiat Oncol Biol Phys, vol.66, issue.2, pp.339-383, 2006.

E. P. Krenning, W. H. Bakker, W. A. Breeman, J. W. Koper, P. P. Kooij et al., Localisation of endocrinerelated tumours with radioiodinated analogue of somatostatin, Lancet Lond Engl, vol.1, issue.8632, pp.242-246, 1989.

S. A. Deppen, J. Blume, A. J. Bobbey, C. Shah, M. M. Graham et al., 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis, J Nucl Med Off Publ Soc Nucl Med, vol.57, issue.6, pp.872-880, 2016.

T. A. Hope, J. Calais, L. Zhang, W. Dieckmann, and C. Millo, 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden, J Nucl Med, vol.60, issue.9, pp.1266-1275, 2019.

J. Strosberg, G. El-haddad, E. Wolin, A. Hendifar, J. Yao et al., Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, N Engl J Med, vol.376, issue.2, pp.125-160, 2017.

J. Teunissen, D. J. Kwekkeboom, M. De-jong, J. Esser, R. Valkema et al., Peptide receptor radionuclide therapy, Best Pract Res Clin Gastroenterol, vol.19, issue.4, pp.595-616, 2005.

J. A. O'donoghue, M. Bardiès, and T. E. Wheldon, Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides, J Nucl Med Off Publ Soc Nucl Med, vol.36, issue.10, pp.1902-1911, 1995.

R. Barone, F. Borson-chazot, R. Valkema, S. Walrand, F. Chauvin et al., Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship, J Nucl Med Off Publ Soc Nucl Med, vol.46, issue.1, pp.99-106, 2005.

H. Schloss, M. Freidberg, S. R. Heatley, G. J. Lo, and T. C. , Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas, Acta Oncol Stockh Swed, vol.28, issue.1, pp.51-56, 1989.

C. Y. Hui, S. Rudra, S. Ma, J. L. Campian, and J. Huang, Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients, J Neurooncol, vol.143, issue.1, pp.129-165, 2019.

A. Braat, T. J. Snijders, T. Seute, and E. Vonken, Will 177Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intraarterial Administration, Cardiovasc Intervent Radiol, vol.42, issue.11, pp.1649-52, 2019.

F. A. Verburg, M. Wiessmann, G. Neuloh, F. M. Mottaghy, and M. Brockmann, Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET/CT in patients with inoperable meningioma, Nukl Nucl Med, vol.58, issue.1, pp.23-30, 2019.

K. Gerster-gilliéron, F. Forrer, H. Maecke, J. Mueller-brand, A. Merlo et al., 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas, J Nucl Med, vol.56, issue.11, pp.1748-51, 2015.

A. Sabet, K. Ezziddin, U. Pape, K. Reichman, T. Haslerud et al., Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate, Eur J Nucl Med Mol Imaging, vol.41, issue.3, pp.505-515, 2014.

R. A. Werner, S. Beykan, T. Higuchi, K. Lückerath, A. Weich et al., The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy, Oncotarget, vol.7, issue.27, pp.41233-41274, 2016.

M. Bartolomei, L. Bodei, D. Cicco, C. Grana, C. M. Cremonesi et al., Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma, Eur J Nucl Med Mol Imaging, vol.36, issue.9, p.1407, 2009.

J. Oddstig, P. Bernhardt, O. Nilsson, and H. Ahlman, Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro, Nucl Med Biol, vol.33, issue.7, pp.841-847, 2006.

J. Oddstig, P. Bernhardt, O. Nilsson, H. Ahlman, and E. Forssell-aronsson, Radiation induces up-regulation of somatostatin receptors 1, 2, and 5 in small cell lung cancer in vitro also at low absorbed doses, Cancer Biother Radiopharm, vol.26, issue.6, pp.759-65, 2011.

K. Seystahl, V. Stoecklein, U. Schüller, E. Rushing, G. Nicolas et al., Somatostatin receptortargeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake, Neuro-Oncol, vol.18, issue.11, pp.1538-1585, 2016.

N. Marincek, P. Radojewski, R. A. Dumont, P. Brunner, J. Müller-brand et al., Somatostatin Receptor-Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial, J Nucl Med, vol.56, issue.2, pp.171-177, 2015.

P. E. Hartrampf, H. Hänscheid, O. Kertels, A. Schirbel, M. C. Kreissl et al., Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma, Clin Transl Radiat Oncol, vol.22, pp.29-32, 2020.

M. C. Kreissl, H. Hänscheid, M. Löhr, F. A. Verburg, M. Schiller et al., Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma, Radiat Oncol Lond Engl, vol.7, p.99, 2012.

R. Laudicella, D. Albano, S. Annunziata, D. Calabrò, G. Argiroffi et al.,

, Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications, Cancers, 2019.

R. V. Parghane, S. Talole, and S. Basu, Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors, World J Nucl Med, vol.18, issue.2, pp.160-70, 2019.

L. Bodei, M. Cremonesi, C. M. Grana, N. Fazio, S. Iodice et al., Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study, Eur J Nucl Med Mol Imaging, vol.38, issue.12, pp.2125-2160, 2011.

F. Minutoli, E. Amato, A. Sindoni, D. Cardile, A. Conti et al., Peptide Receptor Radionuclide Therapy in Patients with Inoperable Meningiomas: Our Experience and Review of the Literature, Cancer Biother Radiopharm, vol.29, issue.5, pp.193-202, 2014.

M. Van-essen, E. P. Krenning, P. P. Kooij, W. H. Bakker, R. A. Feelders et al., Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.10, pp.1599-606, 2006.

A. Sabet, H. Ahmadzadehfar, U. Herrlinger, W. Wilinek, H. Biersack et al., Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report, Radiat Oncol, vol.6, issue.1, p.94, 2011.

A. Sabet, K. Ezziddin, U. Pape, H. Ahmadzadehfar, K. Mayer et al.,

, After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate, J Nucl Med, vol.54, issue.11, pp.1857-61, 2013.

D. J. Kwekkeboom, W. W. De-herder, B. L. Kam, C. H. Van-eijck, M. Van-essen et al., Treatment with the radiolabeled somatostatin analog, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.13, pp.2124-2154, 2008.

H. J. Park, R. J. Griffin, S. Hui, S. H. Levitt, and C. W. Song, Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS), Radiat Res, 2012.

O. Kamel-hasan, R. Kumar, A. S. Kong, G. Oleinikov, K. Ben-haim et al., Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma, J Nucl Med Off Publ Soc Nucl Med, 2020.

D. Heute, H. Kostron, . Guggenberg-e-von, S. Ingorokva, M. Gabriel et al., Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC, J Nucl Med, vol.51, issue.3, pp.397-400, 2010.

G. P. Nicolas, R. Mansi, L. Mcdougall, J. Kaufmann, H. Bouterfa et al.,

. Pharmacokinetics, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect, J Nucl Med, vol.58, issue.9, pp.1435-1476, 2009.